Modification of Antitumor Immunity and Tumor Microenvironment by Resveratrol in Mouse Renal Tumor Model

被引:45
作者
Chen, Liang [1 ]
Yang, Sixing [1 ]
Liao, Wenbiao [1 ]
Xiong, Yunhe [1 ]
机构
[1] Wuhan Univ, Dept Urol, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China
关键词
Resveratrol; Renal cell carcinoma; CD8(+) T cells; Tumor microenvironment; Fas; Fas ligand; Cytokine; CELL CARCINOMA; CANCER-IMMUNOTHERAPY; T-CELLS; CYTOTOXICITY; MECHANISMS; PATHWAYS;
D O I
10.1007/s12013-015-0513-z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Renal cell carcinoma (RCC) microenvironment plays critical roles in antitumor immune response. Resveratrol exhibits a direct antitumor effect in various tumor models. However, the immunomodulatory effect of resveratrol on RCC microenvironment is unknown. In this study, we found that administration of low dose of resveratrol inhibits Renca tumor growth and its inhibition effect depends on CD8(+) T cells. Moreover, the proportion of regulatory T cells is decreased, while the proportion of myeloid-derived suppressor cells does not alter after resveratrol treatment. More importantly, massive amount of activated CD8(+) T cells accumulates in tumor microenvironment in the resveratrol-treated group and shows increased cytotoxicity, as indicated by a higher expression of Fas ligand. We also found that resveratrol switches the expression of T-helper (Th) 2 cytokines such as interleukin (IL)-6 and IL-10 to Th 1 cytokines with dominance of interferon (IFN)-gamma, which increases the expression of Fas in Renca cells. Furthermore, we found resveratrol down-regulates angiogenesis along with decreased level of vascular endothelial growth factor in tumor microenvironment. Our results strongly suggest that resveratrol might be used for RCC immunotherapy through modulating tumor microenvironment.
引用
收藏
页码:617 / 625
页数:9
相关论文
共 28 条
[1]   Interferons, immunity and cancer immunoediting [J].
Dunn, Gavin P. ;
Koebel, Catherine M. ;
Schreiber, Robert D. .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (11) :836-848
[2]   Emerging immunotherapies for renal cell carcinoma [J].
Escudier, B. .
ANNALS OF ONCOLOGY, 2012, 23 :35-40
[3]  
Feng YH, 2002, ACTA PHARMACOL SIN, V23, P893
[4]   Modification of the Tumor Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics [J].
Finke, James H. ;
Rayman, Pat A. ;
Ko, Jennifer S. ;
Bradley, Judy M. ;
Gendler, Sandra J. ;
Cohen, Peter A. .
CANCER JOURNAL, 2013, 19 (04) :353-364
[5]   The immune contexture in human tumours: impact on clinical outcome [J].
Fridman, Wolf Herman ;
Pages, Franck ;
Sautes-Fridman, Catherine ;
Galon, Jerome .
NATURE REVIEWS CANCER, 2012, 12 (04) :298-306
[6]   Innate and adaptive immune cells in the tumor microenvironment [J].
Gajewski, Thomas F. ;
Schreiber, Hans ;
Fu, Yang-Xin .
NATURE IMMUNOLOGY, 2013, 14 (10) :1014-1022
[7]   Resveratrol Prevents Endothelial Cells Injury in High-Dose Interleukin-2 Therapy against Melanoma [J].
Guan, Hongbing ;
Singh, Narendra P. ;
Singh, Udai P. ;
Nagarkatti, Prakash S. ;
Nagarkatti, Mitzi .
PLOS ONE, 2012, 7 (04)
[8]   Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review [J].
Gupta, Kiran ;
Miller, Jeffrey D. ;
Li, Jim Z. ;
Russel, Mason W. ;
Charbonneau, Claudie .
CANCER TREATMENT REVIEWS, 2008, 34 (03) :193-205
[9]   Chemosensitization of tumors by resveratrol [J].
Gupta, Subash C. ;
Kannappan, Ramaswamy ;
Reuter, Simone ;
Kim, Ji Hye ;
Aggarwal, Bharat B. .
RESVERATROL AND HEALTH, 2011, 1215 :150-160
[10]   Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence [J].
Hutson, Thomas E. .
ONCOLOGIST, 2011, 16 :14-22